BCWORLD PHARM Past Earnings Performance
Past criteria checks 4/6
BCWORLD PHARM's earnings have been declining at an average annual rate of -3.4%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 8.7% per year. BCWORLD PHARM's return on equity is 3.6%, and it has net margins of 3.5%.
Key information
-3.4%
Earnings growth rate
-3.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 8.7% |
| Return on equity | 3.6% |
| Net Margin | 3.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Investors Shouldn't Be Too Comfortable With BCWORLD PHARM's (KOSDAQ:200780) Earnings
Mar 18
BCWORLD PHARM (KOSDAQ:200780) Seems To Be Using A Lot Of Debt
Mar 01Does The Market Have A Low Tolerance For BCWORLD PHARM. Co., Ltd.'s (KOSDAQ:200780) Mixed Fundamentals?
Feb 09
Is BCWORLD PHARM. Co., Ltd. (KOSDAQ:200780) A Good Dividend Stock?
Jan 25If You Had Bought BCWorld Pharm (KOSDAQ:200780) Stock A Year Ago, You Could Pocket A 75% Gain Today
Jan 11Do Insiders Own Lots Of Shares In BCWorld Pharm Co., Ltd. (KOSDAQ:200780)?
Dec 26Are BCWorld Pharm's (KOSDAQ:200780) Statutory Earnings A Good Guide To Its Underlying Profitability?
Dec 08Is BCWorld Pharm (KOSDAQ:200780) A Risky Investment?
Nov 18Revenue & Expenses BreakdownBeta
How BCWORLD PHARM makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 75,111 | 2,634 | 20,525 | 1,198 |
| 30 Sep 23 | 76,056 | 6,240 | 16,778 | 5,978 |
| 30 Jun 23 | 76,213 | 5,651 | 16,419 | 6,287 |
| 31 Mar 23 | 76,040 | 481 | 15,963 | 7,901 |
| 31 Dec 22 | 72,703 | 281 | 21,296 | 771 |
| 30 Sep 22 | 68,918 | 255 | 12,743 | 9,180 |
| 30 Jun 22 | 66,489 | -644 | 12,359 | 9,454 |
| 31 Mar 22 | 63,383 | -2,944 | 11,916 | 9,135 |
| 31 Dec 21 | 62,079 | -1,843 | 11,712 | 9,298 |
| 30 Sep 21 | 59,217 | -8,508 | 12,103 | 10,011 |
| 30 Jun 21 | 57,763 | -6,032 | 11,434 | 10,976 |
| 31 Mar 21 | 57,071 | -1,956 | 10,427 | 11,225 |
| 31 Dec 20 | 57,030 | -1,580 | 10,917 | 10,951 |
| 30 Sep 20 | 56,434 | -2,450 | 10,395 | 10,761 |
| 30 Jun 20 | 56,034 | -1,392 | 10,213 | 9,667 |
| 31 Mar 20 | 54,135 | -1,972 | 10,617 | 8,616 |
| 31 Dec 19 | 51,497 | -1,553 | 9,760 | 8,444 |
| 30 Sep 19 | 51,440 | 5,011 | 9,308 | 7,393 |
| 30 Jun 19 | 52,492 | 4,761 | 9,057 | 7,324 |
| 31 Mar 19 | 53,823 | 5,024 | 8,983 | 7,500 |
| 31 Dec 18 | 54,792 | 4,993 | 8,626 | 7,241 |
| 30 Sep 18 | 54,722 | 7,777 | 8,480 | 7,211 |
| 30 Jun 18 | 53,044 | 8,124 | 8,332 | 6,896 |
| 31 Mar 18 | 51,008 | 8,000 | 8,327 | 6,464 |
| 31 Dec 17 | 50,207 | 8,083 | 8,348 | 6,650 |
| 31 Dec 16 | 45,658 | 6,475 | 9,120 | 6,557 |
Quality Earnings: A200780 has high quality earnings.
Growing Profit Margin: A200780's current net profit margins (3.5%) are higher than last year (0.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A200780's earnings have declined by 3.4% per year over the past 5 years.
Accelerating Growth: A200780's earnings growth over the past year (836.3%) exceeds its 5-year average (-3.4% per year).
Earnings vs Industry: A200780 earnings growth over the past year (836.3%) exceeded the Pharmaceuticals industry 34.6%.
Return on Equity
High ROE: A200780's Return on Equity (3.6%) is considered low.